Mineralys (MLYS) | Stock Overview & Key Data
Mineralys Performance Comparison
Stock Range
Today's Range
Low: $36.18
High: $37.99
on September 12, 2025
52 Week Range
Low: $8.24
High: $39.20
on February 25, 2025
on September 11, 2025
All-Time High: $39.20 on September 11, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.9B
EPS
-3.56
P/E Ratio (TTM)
-10.14
Forward P/E
-10.69
P/B Ratio
7.78
PEG Ratio
0.49
Div. Yield
N/A
ROE
-63.21%
Beta
-0.296
Debt to Equity
0.00
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-38.80%
Return on Equity (TTM)
-63.21%
EBITDA
$-203.0M
Net Income (TTM)
$-190.8M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Mineralys MLYS | 2.88B Mid-cap | 6.61% | 174.61% | 148.66% | 182.99% | 202.86% | 215.48% | 101.19% | 101.19% |
| Vertex VRTX | 101.15B Large-cap | -0.40% | 1.74% | -14.24% | -20.36% | -2.77% | -18.72% | 36.18% | 48.66% |
| Alnylam ALNY | 61.07B Large-cap | 3.07% | 8.36% | 52.92% | 92.18% | 99.42% | 75.61% | 118.70% | 252.21% |
| BridgeBio Pharma BBIO | 9.79B Mid-cap | -4.07% | 4.32% | 29.16% | 57.13% | 81.60% | 95.57% | 359.61% | 21.36% |
| Madrigal MDGL | 9.63B Mid-cap | -0.15% | 20.40% | 45.43% | 32.05% | 37.75% | 78.75% | 523.60% | 251.74% |
| Roivant Sciences ROIV | 9.61B Mid-cap | 8.98% | 21.69% | 22.76% | 32.83% | 16.56% | 17.92% | 333.23% | 41.94% |
Ownership & Short Interest
Insider Ownership
1.88%
Institutional Ownership
96.80%
Shares Short
8M
Short Ratio
8.48
Short % of Shares Outstanding
15.10%
Average 10-Day Volume
4M
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is MLYS's 52-week high and low?
- In the last 52 weeks, Mineralys reached a high of $39.20 (on September 11, 2025) and a low of $8.24 (on February 25, 2025).
- What is the market cap and P/E ratio for MLYS?
- Curious about Mineralys's size and valuation? Its market capitalization stands at 2.88B. When it comes to valuation, the P/E ratio (trailing twelve months) is -10.14, and the forward P/E (looking ahead) is -10.69.
- Does MLYS pay dividends? If so, what's the yield?
- As for dividends, Mineralys isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Mineralys's main competitors or similar companies to consider before investing?
When looking at Mineralys, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.15B Healthcare Biotechnology -18.72% 36.18% Alnylam
ALNY61.07B Healthcare Biotechnology 75.61% 118.70% BridgeBio Pharma
BBIO9.79B Healthcare Biotechnology 95.57% 359.61% Madrigal
MDGL9.63B Healthcare Biotechnology 78.75% 523.60% Roivant Sciences
ROIV9.61B Healthcare Biotechnology 17.92% 333.23% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Mineralys Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Mineralys's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -63.21%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for MLYS?
- Looking at Mineralys's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of MLYS stock is held by insiders and institutions?
- Wondering who owns Mineralys stock? Company insiders (like executives and directors) hold about 1.88% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 96.80%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.